Several risk factors for ARIA, such as CAA; the presence of one or more microhemorrhages/superficial siderosis and white matter disease at baseline; a higher baseline amyloid load; hypertension [12]; the initial treatment period (e.g., most instances of ARIA-E occur within the first 3 months of treatment); the type of antibody used [13,14,15,16,17,18,19,20]; higher dosages [11]; an ApoE Ɛ4 genotype, with ApoE Ɛ4 homozygotes posing the greatest risk [15,21,22,23,24]; and anti-thrombin use [12], have been identified. The gene discussed is APOE; the disease is Hypertension.